Total Payments
$632,186
2024 Payments
$63,977
Companies
36
Transactions
456
Medicare Patients
1,132
Medicare Billing
$193,847
Payment Breakdown by Category
Consulting$382,571 (60.5%)
Other$117,920 (18.7%)
Travel$108,318 (17.1%)
Food & Beverage$12,668 (2.0%)
Research$10,446 (1.7%)
Education$262.99 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $382,571 | 109 | 60.5% |
| Travel and Lodging | $108,318 | 138 | 17.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $62,744 | 31 | 9.9% |
| Honoraria | $55,176 | 14 | 8.7% |
| Food and Beverage | $12,668 | 156 | 2.0% |
| Unspecified | $10,446 | 5 | 1.7% |
| Education | $262.99 | 3 | 0.0% |
Payments by Type
General
$621,740
451 transactions
Research
$10,446
5 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | $74,024 | 73 | $0 (2024) |
| Novo Nordisk AS | $65,482 | 25 | $0 (2021) |
| Novo Nordisk Inc | $65,035 | 33 | $0 (2023) |
| Octapharma USA, Inc. | $52,464 | 30 | $0 (2024) |
| PFIZER INC. | $51,739 | 30 | $0 (2024) |
| NOVARTIS PHARMACEUTICALS CORPORATION | $47,853 | 20 | $0 (2023) |
| CSL Behring | $42,080 | 26 | $0 (2021) |
| Takeda Pharmaceuticals U.S.A., Inc. | $32,775 | 24 | $0 (2023) |
| Shire North American Group Inc | $27,462 | 33 | $0 (2019) |
| Genentech USA, Inc. | $25,062 | 28 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $63,977 | 41 | Octapharma USA, Inc. ($34,376) |
| 2023 | $79,279 | 62 | Octapharma USA, Inc. ($16,579) |
| 2022 | $51,068 | 41 | Bayer HealthCare Pharmaceuticals Inc. ($12,662) |
| 2021 | $71,769 | 47 | Novartis Pharmaceuticals Corporation ($10,500) |
| 2020 | $56,838 | 22 | Novartis Pharmaceuticals Corporation ($13,626) |
| 2019 | $99,319 | 86 | Novo Nordisk Inc ($24,978) |
| 2018 | $86,144 | 59 | Novo Nordisk AS ($29,851) |
| 2017 | $123,791 | 98 | Novo Nordisk AS ($32,416) |
All Payment Transactions
456 individual payment records from CMS Open Payments — Page 1 of 19
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/09/2024 | HEMA Biologics, LLC | SevenFact (Biological) | Food and Beverage | In-kind items and services | $38.36 | General |
| Category: Hematology | ||||||
| 12/07/2024 | Regeneron Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $141.59 | General |
| 11/20/2024 | GENZYME CORPORATION | ALTUVIIIO (Biological) | Food and Beverage | In-kind items and services | $120.33 | General |
| Category: Hematology | ||||||
| 11/20/2024 | GENZYME CORPORATION | ALTUVIIIO (Biological) | Food and Beverage | In-kind items and services | $13.66 | General |
| Category: Hematology | ||||||
| 10/31/2024 | SANOFI-AVENTIS U.S. LLC | REZUROCK (Drug) | Food and Beverage | In-kind items and services | $20.36 | General |
| Category: Oncology | ||||||
| 09/08/2024 | Octapharma USA, Inc. | NUWIQ (Biological) | Travel and Lodging | Cash or cash equivalent | $8,239.00 | General |
| Category: COAGULATION | ||||||
| 09/08/2024 | Octapharma USA, Inc. | NUWIQ (Biological) | Honoraria | Cash or cash equivalent | $2,217.00 | General |
| Category: COAGULATION | ||||||
| 09/08/2024 | Octapharma USA, Inc. | NUWIQ (Biological) | Travel and Lodging | Cash or cash equivalent | $961.68 | General |
| Category: COAGULATION | ||||||
| 06/26/2024 | Octapharma USA, Inc. | WILATE - VON WILLEBRAND FACTOR/COAGULATION FACTOR VIII COMPLEX (HUMAN) (Biological) | Travel and Lodging | Cash or cash equivalent | $7,669.00 | General |
| Category: COAGULATION | ||||||
| 06/26/2024 | Octapharma USA, Inc. | WILATE - VON WILLEBRAND FACTOR/COAGULATION FACTOR VIII COMPLEX (HUMAN) (Biological) | Honoraria | Cash or cash equivalent | $2,680.00 | General |
| Category: COAGULATION | ||||||
| 06/26/2024 | Octapharma USA, Inc. | WILATE - VON WILLEBRAND FACTOR/COAGULATION FACTOR VIII COMPLEX (HUMAN) (Biological) | Travel and Lodging | Cash or cash equivalent | $916.02 | General |
| Category: COAGULATION | ||||||
| 06/24/2024 | Regeneron Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $927.00 | General |
| 06/24/2024 | Regeneron Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $463.50 | General |
| 06/23/2024 | Regeneron Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $155.38 | General |
| 06/02/2024 | Bayer Healthcare Pharmaceuticals Inc. | — | Travel and Lodging | In-kind items and services | $228.60 | General |
| 06/01/2024 | Bayer Healthcare Pharmaceuticals Inc. | — | Consulting Fee | Cash or cash equivalent | $11,360.00 | General |
| 06/01/2024 | Bayer Healthcare Pharmaceuticals Inc. | — | Travel and Lodging | In-kind items and services | $655.85 | General |
| 06/01/2024 | Bayer Healthcare Pharmaceuticals Inc. | — | Travel and Lodging | In-kind items and services | $195.62 | General |
| 06/01/2024 | Bayer Healthcare Pharmaceuticals Inc. | — | Food and Beverage | In-kind items and services | $74.25 | General |
| 06/01/2024 | Bayer Healthcare Pharmaceuticals Inc. | — | Food and Beverage | In-kind items and services | $60.75 | General |
| 06/01/2024 | Bayer Healthcare Pharmaceuticals Inc. | — | Food and Beverage | In-kind items and services | $46.11 | General |
| 06/01/2024 | Bayer Healthcare Pharmaceuticals Inc. | — | Food and Beverage | In-kind items and services | $41.21 | General |
| 06/01/2024 | Bayer Healthcare Pharmaceuticals Inc. | — | Food and Beverage | In-kind items and services | $31.62 | General |
| 05/31/2024 | Bayer Healthcare Pharmaceuticals Inc. | — | Travel and Lodging | In-kind items and services | $285.10 | General |
| 05/31/2024 | Bayer Healthcare Pharmaceuticals Inc. | — | Travel and Lodging | In-kind items and services | $195.62 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Efficacy of emicizumab is maintained throughout dosing intervals for bleed prophylaxis | F. Hoffmann-La Roche AG | $3,931 | 1 |
| Bleeding events in people with congenital haemophilia A without factor VIII inhibitors receiving prophylactic factor VIII treatment: A systematic literature review | F. Hoffmann-La Roche AG | $3,627 | 1 |
| A MULTICENTER, NON-INTERVENTIONAL STUDY EVALUATING BLEEDING INCIDENCE, HEALTH-RELATED QUALITY OF LIFE, AND SAFETY IN PATIENTS WITH HEMOPHILIA A UNDER STANDARD-OF-CARE TREATMENT | F. Hoffmann-La Roche AG | $2,579 | 1 |
| ATN-106 | Octapharma USA, Inc. | $308.55 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 214 | 304 | $103,073 | $35,247 |
| 2022 | 5 | 259 | 387 | $129,485 | $47,562 |
| 2021 | 7 | 335 | 556 | $167,756 | $60,675 |
| 2020 | 9 | 324 | 528 | $156,136 | $50,363 |
Total Patients
1,132
Total Services
1,775
Medicare Billing
$193,847
Procedure Codes
26
All Medicare Procedures & Services
26 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 124 | 200 | $69,011 | $24,446 | 35.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 28 | 28 | $13,710 | $4,128 | 30.1% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 25 | 25 | $12,143 | $3,773 | 31.1% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 13 | 21 | $5,583 | $2,068 | 37.0% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Facility | 2023 | 24 | 30 | $2,626 | $832.82 | 31.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 139 | 237 | $80,106 | $30,049 | 37.5% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 33 | 35 | $16,996 | $6,066 | 35.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 35 | 35 | $16,835 | $5,853 | 34.8% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 28 | 52 | $13,000 | $4,782 | 36.8% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Facility | 2022 | 24 | 28 | $2,548 | $812.39 | 31.9% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 135 | 225 | $76,050 | $28,142 | 37.0% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 43 | 145 | $36,250 | $13,607 | 37.5% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 41 | 47 | $22,835 | $8,473 | 37.1% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 35 | 35 | $16,835 | $5,345 | 31.8% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Facility | 2021 | 49 | 67 | $6,097 | $1,894 | 31.1% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2021 | 19 | 23 | $6,049 | $1,849 | 30.6% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2021 | 13 | 14 | $3,640 | $1,365 | 37.5% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 93 | 146 | $49,483 | $14,125 | 28.5% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 49 | 148 | $37,000 | $13,784 | 37.3% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 48 | 51 | $24,786 | $9,250 | 37.3% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 27 | 52 | $8,996 | $3,364 | 37.4% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 36 | 53 | $13,363 | $3,363 | 25.2% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2020 | 37 | 43 | $11,309 | $3,068 | 27.1% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Facility | 2020 | 11 | 11 | $3,630 | $1,283 | 35.4% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 11 | 11 | $5,294 | $1,274 | 24.1% |
About Craig Kessler
Craig Kessler is a Hematology & Oncology healthcare provider based in Washington, District of Columbia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/20/2005. The National Provider Identifier (NPI) number assigned to this provider is 1356340517.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Craig Kessler has received a total of $632,186 in payments from pharmaceutical and medical device companies, with $63,977 received in 2024. These payments were reported across 456 transactions from 36 companies. The most common payment nature is "Consulting Fee" ($382,571).
As a Medicare-enrolled provider, Kessler has provided services to 1,132 Medicare beneficiaries, totaling 1,775 services with total Medicare billing of $193,847. Data is available for 4 years (2020–2023), covering 26 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Washington, DC
- Active Since 07/20/2005
- Last Updated 08/15/2012
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1356340517
Products in Payments
- NovoSeven RT (Drug) $41,808
- NUWIQ (Biological) $40,890
- PROMACTA (Drug) $37,871
- HEMLIBRA (Biological) $31,482
- Idelvion (Biological) $27,352
- Jivi (Drug) $25,847
- BENEFIX (Biological) $19,340
- Hemlibra (Biological) $15,324
- Tavalisse (Drug) $12,597
- Afstyla (Biological) $12,018
- ADVATE (Biological) $11,750
- WILATE - VON WILLEBRAND FACTOR/COAGULATION FACTOR VIII COMPLEX (HUMAN) (Biological) $11,265
- NovoSeven (Biological) $9,995
- Kovaltry (Drug) $8,771
- ADYNOVATE (Biological) $7,244
- Doptelet (Drug) $6,080
- NovoSeven RT (Biological) $4,320
- Alphanate (Biological) $4,188
- IXINITY (Drug) $3,414
- Mulpleta (Drug) $1,803
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Washington
Imad Tabbara, M.d, M.D
Hematology & Oncology — Payments: $1.8M
Hematology & Oncology $1.8M
John Marshall
Hematology & Oncology — Payments: $770,250
Hematology & Oncology $770,250
Dr. Catherine Broome, Md, MD
Hematology & Oncology — Payments: $693,161
Hematology & Oncology $693,161
Claudine Isaacs
Hematology & Oncology — Payments: $406,847
Hematology & Oncology $406,847
Muhammad Mirza, M.d, M.D
Hematology & Oncology — Payments: $118,419
Hematology & Oncology $118,419
Dr. Christopher Gallagher, M.d, M.D
Hematology & Oncology — Payments: $107,252
Hematology & Oncology $107,252